SRNE - Sorrento Therapeutics' subsidiary signs second contract for 10M COVISTIX tests sale to Mexico market

Sorrento Therapeutics' (NASDAQ:SRNE) subsidiary, Sorrento Therapeutics Mexico executed a second contract with a large distributor for the sale and distribution of up to 10M COVISTIX tests for the Mexican market. Earlier, Sorrento Mexico had signed a contract with a leading local distributor for up to 5M COVISTIX tests in Mexico, bringing the total number of tests to 15M until date. Since its commercial launch in July, the COVISTIX COVID-19 Virus Rapid Antigen Detection Test has been well received for its ease of use and rapid generation of results. The rapid COVISTIX test provides a much needed tool to mass screen the population for sports events, school attendance and all other family and social gatherings as well as for businesses. SRNE trades 1.2% higher premarket.

For further details see:

Sorrento Therapeutics' subsidiary signs second contract for 10M COVISTIX tests sale to Mexico market